Skip to main content
. Author manuscript; available in PMC: 2016 Nov 22.
Published in final edited form as: J Thorac Oncol. 2013 May;8(5):658–661. doi: 10.1097/JTO.0b013e31828d08ae

TABLE 4.

Summary of Selected Phase II/Phase III Trials Containing Vandetanib Monotherapy Arms and Clinical Outcome

Trials with
Vandetanib
Monotherapy
Arms		 Trial
Phase		 Median
PFS (mo)		 HR
p 		Median
OS (mo)		 HR
p
Current trial II 1.81 N/A 6.5 N/A
  EGFR mutation 3.2 5.9
ZEPHYR III
  Lee et al.11
  Vandetanib arm 1.9 0.63 8.5 0.95
  Placebo arm 1.8 p < 0.001 7.8 p = 0.527
Natale et al.2 III
  Vandetanib arm 2.6 0.98 6.9 1.01
  Erlotinib arm 2.0 p = 0.72 7.8 p = 0.83
Natale et al.10 II
  Vandetanib arm 2.75a 0.69a 6.1 1.19
  Gefitinib arm 2.03a p = 0.025 7.4 p = 0.34
a

Results reported are before cross-over.

PFS, progression-free survival; HR, hazard ratio; OS, overall survival; N/A, not applicable; ZEPHYR, International, Randomised, Double-Blind Parallel Group, Multicenter Study to Assess the Efficacy of ZD6474 (ZACTIMA) plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB–IV) Non-Small Cell Lung cancer (NSCLC) after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI).